Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 28790118.
- Also identified by DOI 10.1158/1078-0432.CCR-17-1799.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
T-cell costimulation and coinhibition can be respectively exploited by blocking and agonist mAbs. Both strategies can be synergistically combined in mouse models. Early clinical results from combinations of anti-PD-1 mAbs in conjunction with agonist anti-CD137 (4-1BB) mAbs show excellent safety and promising efficacy. <i>Clin Cancer Res; 23(18); 5326-8. ©2017 AACR</i><i>See related article by Tolcher et al., p. 5349</i>.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- B7-H1 Antigen
- Molecular Targeted Therapy
- Neoplasms
- Programmed Cell Death 1 Receptor
- Tumor Necrosis Factor Receptor Superfamily, Member 9